Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03913195
Recruitment Status : Recruiting
First Posted : April 12, 2019
Last Update Posted : June 13, 2019
Sponsor:
Collaborator:
Westat
Information provided by (Responsible Party):
TaiMed Biologics Inc.

Brief Summary:
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push". An initial "Sentinel Group" of 5 participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing concentration and decreasing administration time until undiluted IV Push over 30 seconds is achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored.

Condition or disease Intervention/treatment Phase
HIV-1-infection Drug: ibalizumab-uiyk Phase 3

Detailed Description:

This goal of this Phase 3 is to evaluate the safety and pharmacokinetics of administering Trogarz 800 mg once every two weeks as an undiluted IV Push over 30 seconds in clinically stable HIV-1 infected patients currently receiving treatment with a stable Trogarz-containing regimen.

The first five (5) patients enrolled will comprise the Sentinel Group. Patients six (6) through twenty (20) (the Core Group) will not be screened until the Sentinel Group has completed Day 99 (14 weeks) of the study and the DSMB has reviewed the data accumulated and given approval for enrollment of the Core Group to proceed.

The Sentinel Group will receive 2 successive doses of Trogarzo in accordance with the prescribing information. Safety and pharmacokinetic data from these administrations will serve as the comparator for each study participant. Beginning at Day 29 and continuing through Day 85, Sentinel Group participants will begin receiving the prescribed dosage of Trogarzo once every two weeks through Day 85 of the study on a schedule of increasing drug concentration and decreasing administration time at each visit to achieve an undiluted IV Push administration of Trogarzo over 30 seconds.

After review of data from the Sentinel Group by a DSMB, if approved the study will continue with enrollment of the Core Group. The Core Group will receive 2 successive doses of Trogarzo in accordance with the prescribing information. Safety and pharmacokinetic data from these administrations will serve as the comparator for each study participant. Thereafter, Core Group participants will receive the prescribed dosage of Trogarzo via undiluted IV Push over 30 seconds through Day 71 of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" Over a Reduced Interval in Clinically Stable HIV-1 Infected Trogarzo™ Experienced Patients
Actual Study Start Date : May 30, 2019
Estimated Primary Completion Date : May 15, 2020
Estimated Study Completion Date : May 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Sentinel Group
Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
Drug: ibalizumab-uiyk
Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Other Name: Trogarzo

Experimental: Core Group
Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
Drug: ibalizumab-uiyk
Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Other Name: Trogarzo




Primary Outcome Measures :
  1. Safety of Trogarzo given as IV Push over 30 seconds in Sentinel Group [ Time Frame: 12 weeks ]
    Percent of subjects in Sentinel Group who complete 100% of all Trogarzo administrations given as infusion/bolus/push as per protocol

  2. Safety of Trogarzo given as IV Push over 30 seconds in Core Group [ Time Frame: 10 weeks ]
    Percent of subjects in Core Group who complete 100% of all Trogarzo administrations given as infusion/bolus/push as per protocol

  3. Pharmacokinetics(1) of Trogarzo infusion versus IV Push in Sentinel Group [ Time Frame: Day 1 infusion versus Day 85 IV Push ]
    Ratio of Area Under the Curve of Serum levels of Trogarzo given by 15 minute infusion versus Area Under the Curve of Serum levels of Trogarzo given by IV Push over 30 seconds

  4. Pharmacokinetics(2) of Trogarzo infusion versus IV Push in Sentinel Group [ Time Frame: Day 1 infusion versus Day 85 IV Push ]
    Ratio of Trough Serum levels of Trogarzo given by 15 minute infusion versus Trough Serum levels of Trogarzo given by IV Push over 30 seconds

  5. Pharmacokinetics(1) of Trogarzo infusion versus IV Push in Core Group [ Time Frame: Day 1 infusion versus Day 71 IV Push ]
    Ratio of Area Under the Curve of Serum levels of Trogarzo given by 15 minute infusion versus Area Under the Curve of Serum levels of Trogarzo given by IV Push over 30 seconds

  6. Pharmacokinetics(2) of Trogarzo infusion versus IV Push in Core Group [ Time Frame: Day 1 infusion versus Day 71 IV Push ]
    Ratio of Trough Serum levels of Trogarzo given by 15 minute infusion versus Trough Serum levels of Trogarzo given by IV Push over 30 seconds


Secondary Outcome Measures :
  1. Percent of subjects in the Sentinel Group who fail to maintain virologic control [ Time Frame: 99 days ]
    Percent of subjects in the Sentinel group who experience a sustained increase in log HIV-1 RNA levels of greater than 0.5log from baseline

  2. Percent of subjects in the Core Group who fail to maintain virologic control [ Time Frame: 84 days ]
    Percent of subjects in the Core group who experience a sustained increase in log HIV-1 RNA levels of greater than 0.5log from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are capable of understanding and have voluntarily signed the informed consent document
  2. Currently receiving a stable Trogarzo-containing ARV regimen for a minimum of 3 months, and no change in background ARVs anticipated over the period of study participation; a stable regimen is defined as having no changes in dose or frequency and no interruptions greater than or equal to 2 weeks during the 3 month period
  3. Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before Screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV
  4. Are able and willing to comply with all protocol requirements and procedures
  5. Are 18 years of age or older
  6. Have a life expectancy that is >6 months.
  7. Have a viral load <1,000 copies/mL at Screening
  8. CD4+ T-cell count > 50 cells/mm3 at Screening

Exclusion Criteria:

  1. Any active AIDS-defining illness according to the Centers for Disease Control and Prevention (CDC) Revised Surveillance Case Definitions for HIV Infection 2008 (MMWR Vol.57/No. RR-10, Appendix A), or history of the same during the 3 months preceding Screening, with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to HIV
  2. Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study
  3. Any significant acute illness within 1 week before the initial administration of study drug
  4. Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.
  5. Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 12 weeks before Enrollment
  6. Any vaccination within 7 days before Day 1
  7. Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding
  8. Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations
  9. Any radiation therapy during the 28 days before first administration of study medication
  10. Any Grade 3 or 4 laboratory abnormality according to the Division of AIDS grading scale, except for the following asymptomatic Grade 3 events:

    • triglyceride elevation
    • total cholesterol elevation any Grade 3 or 4 reduction in CD4+ T cell counts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913195


Contacts
Layout table for location contacts
Contact: Tracy Wolbach 240-453-2658 tracywolbach@westat.com
Contact: Christine Anderson, PhD 713-353-7911 christineanderson@westat.com

Locations
Layout table for location information
United States, California
Anthony Mills MD Inc. Recruiting
Los Angeles, California, United States, 90069
Contact: Joey Fragoso    310-550-2271    joey.fragoso@millsclinicalresearch.com   
Contact: Ron Knight    310.550.2271    ron@tonymillsmd.com   
Principal Investigator: Tony Mills, MD         
Anthony Mills, MD, Inc. Recruiting
Los Angeles, California, United States, 90069
Contact: Ron Knight, CRRP    310-550-2271    ron@tonymillsmd.com   
Contact: Frank Capilla    310-550-2271    frank.capilla@millsclinicalresearch.com   
Principal Investigator: Tony Mills, MD         
Sponsors and Collaborators
TaiMed Biologics Inc.
Westat
Investigators
Layout table for investigator information
Study Chair: Martin Markowitz, MD TaiMed Biologics Inc. - Consultant

Layout table for additonal information
Responsible Party: TaiMed Biologics Inc.
ClinicalTrials.gov Identifier: NCT03913195     History of Changes
Other Study ID Numbers: TMB-302
First Posted: April 12, 2019    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be shared with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by TaiMed Biologics Inc.:
HIV
ibalizumab
MDR HIV
Additional relevant MeSH terms:
Layout table for MeSH terms
Ibalizumab
Antibodies, Monoclonal
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs